| Dolutegravir | ViiV | Approved | -
Very high barrier to resistance and better regimen durability
-
Reduced manufacturing cost
-
Reduced side effects compared with efavirenz
-
Potential for first- or second-line treatment
-
More rapid decrease in viral load may increase efficacy for prevention of mother-to-child transmission among women initiating ART late in gestation
-
Low dosage convenient for pediatric formulations
-
May not reduce efficacy of progestin-containing contraceptive implants, which is a possible concern with efavirenz
|
| TAF | Gilead | Late Phase III | -
Lower risk of renal and bone toxicity than TDF
-
Lower manufacturing cost than TDF
-
Potential for first- or second-line treatment, with possible greater efficacy than TDF for viruses resistant to some nucleosides/nucleotides
|
| Doravirine | Merck | Early Phase III | -
Lower rates of central nervous system adverse events than efavirenz reported in phase II studies
-
Possible low manufacturing cost given low dose
-
May have better activity against many non-nucleoside reverse transcriptase resistant isolates common in sub-Saharan Africa, leading to possible utility in second-line combinations
-
Characteristics (lack of food requirement, shorter half-life, lower potential for TB medication interactions) might make it a better partner for dolutegravir than rilpivirine as part of a simplified, low-cost 2-drug maintenance regimen
|